Form 4 Filing for Xynos Konstantinos

This filing reports a late submission of Form 4 by Xynos Konstantinos, Chief Medical Officer at Replimune Group, Inc. The delay was due to an administrative error. The filing details two transactions: the acquisition of 50,000 shares of the Issuer's common stock and the grant of an employee stock option for 75,000 shares. The shares acquired are subject to vesting conditions, with 25% vesting on May 15, 2027, and the remainder vesting in installments until May 15, 2030. The stock option also has a staggered vesting schedule, with 25% vesting on April 1, 2027, and the rest vesting monthly over the following three years. The reported transactions were made on April 1, 2026. The filing is signed by Shawn Glidden as attorney-in-fact.